Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 6Thoracic 1Lymphoid 1Genitourinary 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 7Melanoma 1Lymphoma, T-Cell 1Lung Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

pembrolizumab 92Nivolumab 57Cyclophosphamide 22Ipilimumab 17atezolizumab 15Magnetic Resonance Spectroscopy 14Specimen Handling 13Radiosurgery 13Paclitaxel 13Interleukin-2 12Docetaxel 12fludarabine 11Carboplatin 11Pemetrexed 10spartalizumab 9Biopsy 9durvalumab 8Cisplatin 8Radiotherapy 7Immune Checkpoint Inhibitors 7Blood Specimen Collection 7cemiplimab 6avelumab 6aldesleukin 6Taxes 6Gemcitabine 6Drug Therapy 6Bevacizumab 6trametinib 5tislelizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × ProMune × Thoracic × Clear all
NCT00043368 2009-03-12

PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)

Pfizer

Phase 2 Completed
31 enrolled
BreastDermatologicGenitourinaryLymphoidThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡